ImmunoGen, Inc. (NASDAQ:IMGN) reported Q3 2017 earnings this Morning, coming in at ($0.61) per share, missing Wall Street’s estimates of ($0.19) per Share. Revenue for the quarter came in at $8.50 million beating analyst estimates of $26.09 million
Analyst Coverage For ImmunoGen, Inc. (NASDAQ:IMGN)
These are 1 Sell Rating, 2 Hold Ratings, 5 Buy Ratings .
The current consensus rating for ImmunoGen, Inc. (NASDAQ:IMGN) is Buy (Score: 2.50) with a consensus target price of $8.05 , a potential (64.96% upside)Recent Insider Trading for ImmunoGen, Inc. (NASDAQ:IMGN)
- On 9/15/2017 Craig Barrows, VP, sold 37,050 with an average share price of $6.81 per share and the total transaction amounting to $252,310.50.
- On 9/13/2017 Craig Barrows, VP, sold 14,600 with an average share price of $6.95 per share and the total transaction amounting to $101,470.00.
- On 12/15/2016 Mark Alan Goldberg, Director, bought 20,000 with an average share price of $1.80 per share and the total transaction amounting to $36,000.00.
- On 11/8/2016 Mark J Enyedy, CEO, bought 25,000 with an average share price of $1.83 per share and the total transaction amounting to $45,750.00.
- On 11/2/2016 Craig Barrows, Insider, bought 10,000 with an average share price of $1.71 per share and the total transaction amounting to $17,100.00.
- On 11/2/2016 Richard J Gregory, VP, bought 16,600 with an average share price of $1.78 per share and the total transaction amounting to $29,548.00.
Recent Trading for ImmunoGen, Inc. (NASDAQ:IMGN) Shares of ImmunoGen, Inc. closed the previous trading session at with shares trading hands.